IDM Pharma provides update on mifamurtide (L-MTP-PE) regulatory status following june meeting of european comm INE, Calif.- IDM Pharma, Inc.
Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133).
The Company expects to complete the...
Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. Manufacturing Subsidiary Staffing to be Increased AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc.(NASDAQ:INGN - News) today announced a re-allocation of employees to focus on regulatory review and commercial activities.
Kalaignar 'fails' to check Sun's growth at 0159 hrs The much-hyped launch of 'Kalaignar TV' has failed to check the growth of Sun TV Network in Tamil Nadu.Rather the Sun TV Network claims that its channels have upped their total market share in Tamil Nadu since the launch of ...
Introgen seeks US & European approval for Advexin Introgen Therapeutics, Inc.submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) requesting marketing approval for Advexin p53 therapy to treat recurrent, refractory head and neck cancer.
Centocor, Inc. submits application to FDA requesting approval of Golimumab for the treatment of Rheumatoid Art HORSHAM, Pa.- Centocor, Inc.
announced today that a Biologics License Application (BLA) has been submitted to the U.S.
Food and Drug Administration (FDA) requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous...
UCB's Cimzia filed with EMEA for treatment of rheumatoid arthritis 'Along with a fast onset of action, Cimzia has been shown to rapidly reduce the rate of progression of joint damage and to improve measurements of patients' physical function,' said Olav Hellebo, President of Inflammation Operations for UCB....
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Comm IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.(Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133).
The...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Comm IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.(Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133).
The...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Comm IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.(Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133).
The...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Comm IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.(Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133).
The...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Comm IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.(Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133).
The...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Comm IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.(Nasdaq: IDMI) today announced that the CHMP, following their June 2008 meeting, has requested additional data analyses from the Phase 3 L-MTP-PE trial (INT-0133).
The...
UCB files MAA with EMEA for Cimzia, as a treatment for rheumatoid arthritis - Quick Facts UCB NPV (UCBJF.PK) said it filed a Marketing Authorization Application, or MAA, with the European Medicines Agency requesting the approval of Cimzia, or certolizumab pegol, as a subcutaneous treatment for adults with moderate to severe...
UCB files Cimzia with EMEA Brussels, Belgium-based UCB has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for approval of Cimzia as a subcutaneous treatment for adults with moderate to severe active rheumatoid...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
BRUSSELS, BELGIUM - July 1st...
UCB files MAA with EMEA for Cimzia, as a treatment for rheumatoid arthritis - Quick Facts (RTTNews) - Tuesday, UCB NPV (UCBJF.PK: News, Chart, Quote ) said it filed a Marketing Authorization Application, or MAA, with the European Medicines Agency requesting the approval of Cimzia, or certolizumab pegol, as a subcutaneous...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
BRUSSELS, BELGIUM - July 1st...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis BRUSSELS, BELGIUM -- (MARKET WIRE) -- 07/01/08 -- The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha)...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
BRUSSELS, BELGIUM - July 1st...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis -- The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
BRUSSELS, BELGIUM - July...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis AM BRUSSELS, BELGIUM, July 1 / MARKET WIRE/ -- The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha)...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis -- The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
BRUSSELS, BELGIUM - July...
UCB's Cimzia(R) filed with EMEA for treatment of rheumatoid arthritis - The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
BRUSSELS, BELGIUM - July...
UCB's Cimzia filed with EMEA for treatment of rheumatoid arthritis (GMT+1) The European marketing authorisation application for Cimzia has been filed.Subject to approval, Cimzia will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
BRUSSELS, BELGIUM -...
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe - Introgen Therapeutics, Inc.(NASDAQ:INGN) submitted a Biologics License Application (BLA) to the U.S.
Food and Drug Administration (FDA) requesting marketing approval for ADVEXIN(R) p53 therapy to treat recurrent, refractory head and...
